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Glycans are key determinants of host range and transmissibility in several pathogens. In the case of adeno-associated viruses
(AAV), different carbohydrates serve as cellular receptors in vitro; however, their contributions in vivo are less clear. A particu-
larly interesting example is adeno-associated virus serotype 9 (AAV9), which displays systemic tropism in mice despite low en-
dogenous levels of its primary receptor (galactose) in murine tissues. To understand this further, we studied the effect of modu-
lating glycan binding avidity on the systemic fate of AAV9 in mice. Intravenous administration of recombinant sialidase
increased tissue levels of terminally galactosylated glycans in several murine tissues. These conditions altered the systemic tro-
pism of AAV9 into a hepatotropic phenotype, characterized by markedly increased sequestration within the liver sinusoidal en-
dothelium and Kupffer cells. In contrast, an AAV9 mutant with decreased glycan binding avidity displayed a liver-detargeted
phenotype. Altering glycan binding avidity also profoundly affected AAV9 persistence in blood circulation. Our results support
the notion that high glycan receptor binding avidity appears to impart increased liver tropism, while decreased avidity favors
systemic spread of AAV vectors. These findings may not only help predict species-specific differences in tropism for AAV9 on the
basis of tissue glycosylation profiles, but also provide a general approach to tailor AAV vectors for systemic or hepatic gene
transfer by reengineering capsid-glycan interactions.
The cell surface glycocalyx contains many glycans terminatedwith sialic acid moieties. Variability in the extent, type, and
linkage of sialylation between different hosts is exploited by sev-
eral pathogens during infection (21, 33). Sialoglycans/asialogly-
cans have also been implicated as cell surface receptors for differ-
ent strains of adeno-associated virus (AAV) in vitro (1, 23). The
latter are nonpathogenic, helper-dependent parvoviruses, cur-
rently being evaluated in phase I to III clinical trials as vectors for
gene therapy (20). Over 150 different strains have been isolated
from human and primate tissues to date, and these AAV isolates
display striking differences in capsid structure, receptor usage,
and tissue tropism within different hosts (1, 4, 31). A better un-
derstanding of the mechanisms underlying AAV tropism in dif-
ferent hosts could help guide the selection of preclinical animal
models for evaluating AAV vectors and possibly predict outcomes
in human gene therapy clinical trials.
Glycan receptors for different AAV serotypes include heparan
sulfate for AAV serotype 2 (AAV2) (30), N-linked 2,3-/2,6-
sialic acid for AAV1/AAV6 (36), N-linked 2,3-sialic acid for
AAV5 (35), O-linked 2,3-sialic acid for AAV4 (12), and 1,4-
galactose for AAV9 (6, 28). In addition, various coreceptors, such
as integrins and growth factor receptors, have been implicated in
AAV infection in vitro (1, 23). Structural analysis of AAV capsids
in conjunction with mutagenesis studies has provided a better
understanding of the molecular determinants of AAV capsid-gly-
can interactions. For instance, crystallographic and/or cryoelec-
tron microscopy-based analysis has enabled mapping of the role
of critical amino acid residues involved in heparan sulfate recog-
nition by AAV2, AAV-DJ, AAV3B, and AAV6 capsids (17–19, 22,
24, 37). Recently the binding site of galactose on AAV9 capsids was
mapped using a combination of mutagenesis and computational
modeling tools (5). The structural/molecular basis for recognition
of sialoglycans/asialoglycans by the corresponding AAV serotypes
is currently unknown.
Despite the increasing knowledge of AAV-glycan interactions
in vitro, the underlying molecular bases for differential tissue tro-
pisms displayed by AAV serotypes in vivo is not well understood.
For instance, AAV2, which utilizes heparan sulfate proteoglycans
for cell surface attachment, is a hepatotropic strain, while AAV1,
which binds N-linked 2,3-/2,6-sialic acid, displays cardiac/
muscle tropism (4). In contrast, AAV9, which displays systemic,
multiorgan tropism within different hosts (7, 15, 38), utilizes ter-
minal galactose as its primary receptor (6, 28). The current study
seeks to understand exactly how variations in host glycosylation
patterns can affect AAV tissue tropism in mice, using AAV9-ga-
lactose interactions as a model. The study hinges on a two-
pronged approach, the first of which exploits our preliminary ob-
servation that tissue sialoglycan/asialoglycan levels can be readily
modulated by enzymatic treatment in vivo. Briefly, intravenously
administered sialidase afforded a dramatic increase in the density
of asialoglycans (terminal galactose residues) across multiple tis-
sues, which markedly altered the systemic behavior of AAV9 in
mice. In the second part of this study, we carried out the systemic
evaluation of a mutant AAV9 displaying low glycan binding avid-
ity in normal mice. Our results demonstrate that altered tissue
glycosylation patterns and/or glycan binding affinity can result in
sharply contrasting liver uptake and blood circulation profiles of
AAV in vivo.
MATERIALS AND METHODS
Biochemical reagents. Recombinant sialidase (neuraminidase type III
from Vibrio cholerae) was obtained from Sigma-Aldrich (St. Louis, MO).
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Erythrina cristagalli (ECL) and Maackia amurensis I (MAL-I) lectins were
purchased from Vector Laboratories (Burlingame, CA). Monoclonal an-
tibodies (MAbs) against the endothelium-specific marker FcRII/III/IV
(rat 2.4G2 anti-CD16/CD32) (9) was obtained from BD Biosciences (San
Jose, CA), and Kupffer cell-specific marker (rat anti-F4/80) (9) was ob-
tained from Abcam (Cambridge, MA). Fluorophore-conjugated second-
ary antibodies (goat anti-rat or anti-mouse) were obtained from Invitro-
gen (Carlsbad, CA). The ADK9 mouse anti-capsid MAb recognizing
intact AAV9 capsids was a kind gift from Jürgen Kleinschmidt (German
Cancer Research Center [DKFZ], Heidelberg, Germany).
AAV production. HEK293 cells were maintained at 37°C in 5% CO2
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and penicillin-streptomycin-amphotericin B. The follow-
ing plasmids were generated in the laboratory as described previously (26)
or obtained from the University of North Carolina (UNC) vector core
facility: (i) the pXR9 plasmid encoding rep2 and cap9, (ii) the plasmid
pXX6-80 containing adenoviral helper genes, and (iii) the vector cassette
pTR-CBA-Luciferase or pTR-CBA-tdTomato encoding the chicken beta-
actin (CBA) promoter and the luciferase or a red fluorescent protein,
tdTomato, reporter transgene, respectively. AAV9 vectors packaging TR-
CBA-Luc or TR-CBA-tdTomato were produced by the triple-transfection
method (10), followed by cesium chloride density gradient ultracentrifu-
gation and dialysis against 1 phosphate-buffered saline (PBS) overnight
with two changes. Viral titers were determined by quantitative PCR
(qPCR) using primers (IDT Technologies, Ames, IA) specific for the CBA
promoter (forward, 5=-CGT CAA TGG GTG GAG TAT TT-3=; reverse,
5=-GCG ATG ACT AAT ACG TAG ATG-3=) or the Luc transgene region
(forward, 5=-AAA AGC ACT CTG ATT GAC AAA TAC-3=; reverse, 5=-
CCT TCG CTT CAA AAA ATG GAA C-3=). Viral titers for different
vector preparations typically ranged from 2  1012 to 5  1012 vector
genome-containing particles (vg) per ml.
Cell surface binding assay. CHO Lec2 cells deficient in terminal sialic
acid moieties were seeded at a density of 104 cells/well in 96-well plates and
maintained in an incubator at 37°C and 5% CO2 overnight. Prior to add-
ing virus particles, the cells were prechilled to 4°C for 30 min, followed by
incubation with AAV9 or AAV9-W503R particles at a multiplicity of in-
fection (MOI) of 1  102, 5  102, 1  103, 5  103, 1  104, 5  104, 1 
105, or 5  105 vg/cell for 1.5 h at 4°C. The cells were then subjected to
three washes with ice-cold 1 PBS to remove unbound virions. Cell sur-
face-bound virions were collected, along with cell lysates, following three
freeze-thaw cycles, and vg copy numbers/cell were determined using
quantitative PCR as outlined previously. Binding curves were generated
using GraphPad Prism 5 software by applying the single-site binding model
[Y  Bmax  X/(Kd=  X)], where Y represents the number of bound
virions/cell determined by quantitative PCR, X represents the MOI, Bmax
is the maximum binding capacity, and Kd= is the observed dissociation
constant. The binding potential is defined as Bmax/Kd= and serves as a
measure of glycan binding avidity.
Live-animal studies. All in vivo experiments were carried out using 6-
to 8-week old female BALB/c mice (Jackson Laboratories, Bar Harbor,
ME) maintained and treated in accordance with National Institutes of
Health guidelines and as approved by the IACUC at UNC—Chapel Hill.
Sialidase (neuraminidase type III from V. cholerae; 200 milliunits) or PBS
was administered through intravenous injection 3 h prior to AAV9-CBA-
Luc (5  1010 vg) by the same route. Luciferase transgene expression in
live animals was monitored at the indicated time points for each experi-
ment using a Xenogen IVIS Lumina imaging system (Perkin Elmer/Cali-
per Life Sciences, Waltham, MA) following intraperitoneal injection of
D-luciferin substrate (120 mg/kg of body weight; Nanolight, Pinetop, AZ).
Bioluminescent image analysis was conducted using Living Image soft-
ware (Perkin Elmer/Caliper Life Sciences, Waltham, MA), and luciferase
expression is reported in relative light units (RLU) (photons/s per cm2 per
steradian).
Quantitation of luciferase expression. The same group of mice were
sacrificed at the indicated time points, and the hearts and livers were
harvested. Approximately 50 mg of each tissue was homogenized in 150 l
of passive lysis buffer (Promega, Madison, WI) using a Tissue Lyser II
system (Qiagen, Valencia, CA). Tissue lysates were centrifuged at 8,000
rpm for 2 min to pellet debris, and 50 l of the supernatant was trans-
ferred to 96-well plates for luminometric analysis using a Victor2 lumi-
nometer (Perkin Elmer, Waltham, MA). The total protein concentration
in tissue lysates was determined using the Bradford assay (Bio-Rad, Her-
cules, CA).
Quantitation of viral genome biodistribution. Approximately 100 l
of supernatant from tissue lysates obtained as mentioned above was pro-
cessed using a DNeasy kit (Qiagen, Valencia, CA) to extract host and
vector genomic DNAs. Vector genome (luciferase) and mouse lamin gene
(a housekeeping gene serving as the internal standard) copy numbers
were determined from 100 ng of total extracted DNA using quantitative
PCR as described previously.
Immunohistology. For lectin-staining studies, sialidase (neuramini-
dase type III from V. cholerae; 400 milliunits) in 150 l of PBS or PBS
alone was first administered via tail vein injection. At 3 h postadministra-
tion, the mice were anesthetized by intraperitoneal injection of avertin
(0.2 ml/10 g of a 1.25% solution) and perfused transcardially with 20 ml of
PBS and then with 20 ml of freshly prepared 4% paraformaldehyde (Sig-
ma-Aldrich, St. Louis, MO) in PBS. Cardiac, liver, brain, and muscular
tissues were fixed at 4°C overnight and then sectioned into 40-m slices
using a Leica vibrating-blade microtome (Leica Microsystems, Buffalo
Grove, IL). The sections were blocked in 10% goat serum in 1 PBS
containing 0.1% Triton X-100 (PBS-T) for 1 h at room temperature prior
to incubation with primary antibodies (10 g/ml CD16/CD32 or F4/80
MAb and 1:10 dilution of ADK9 in hybridoma medium) for 24 h at 4°C.
Antibody binding was localized using fluorophore-conjugated secondary
antibodies diluted 1:1,000 in 3% goat serum in PBS-T for 1 h at 4°C.
Specifically, Alexa Fluor 647 goat anti-rat IgG(HL) (Invitrogen A21247;
2 mg/ml; 1:500 dilution) was used to recognize rat anti-mouse-CD16/
CD32 and rat anti-mouse-F4/80, and Alexa Fluor 594 goat anti-mouse
IgG(HL) (Invitrogen A11005; 2 mg/ml; 1:500 dilution) was utilized to
detect ADK9 MAb, which binds to intact AAV9 capsids. When indicated,
the sections were further stained with 30 g/ml of FITC-labeled ECL or
MAL-I lectin in 3% blocking solution. After three washes with PBS to
remove unbound antibodies and lectins, the sections were mounted un-
der coverslips in Prolong gold anti-fade reagent with DAPI (4=,6-di-
amidino-2-phenylindole) (Invitrogen P36935). Tissues harvested from
untreated mice were utilized as controls. Four-color fluorescence images
were acquired using a Zeiss 710 confocal laser scanning microscope
equipped with a spectral detection system for finer separation of fluoro-
chromes. Image processing was carried out using LSM viewer and Image
J software.
To compare the transduction profiles of AAV9 and AAV9-W503R in
live animals, PBS (mock treatment), AAV9-CBA-tdTomato (5  1010 vg),
and AAV9-CBA-tdTomato (5  1010 vg) were injected into BALB/c mice
through the tail vein. Two weeks postinfection, the animals were anesthe-
tized using intaperitoneal avertin (0.2 ml/10 g of a 1.25% working solu-




Cp  A  e
x  B  ex
Tissue-to-blood compartment
distribution rate constant
k21  (A    B  )/(A  B)
Blood elimination rate constant ke    /k21
Blood-to-tissue compartment
distribution rate constant
k12      k21  ke
Distribution half-life t1/2,dis  ln2/k12
Elimination half-life t1/2,e  ln2/ke
a Cp is the viral genome copy number in plasma; x is the time interval. A, B, , and 
are bioexponential parameters.
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tion), followed by transcardial perfusion with 20 ml of PBS and 20 ml of
4% paraformaldehyde in PBS. Tissues were fixed in 4% paraformaldehyde
in PBS overnight at 4°C and sectioned into 40-m slices using a Leica
vibrating-blade microtome. The tissue sections were mounted under cov-
erslips using Prolong gold antifade reagent with DAPI. Red fluorescent
images were taken using an Olympus epifluorescence microscope
equipped with a 10 objective and a Hamamatsu digital camera.
Pharmacokinetic analysis. Sialidase (neuraminidase type III from V.
cholerae; 200 milliunits) or 100 l of PBS was injected intravenously via
the mouse tail vein. AAV9-CBA-Luc (5  1010 vg) was injected by the
same route 2 h later. For pharmacokinetic analysis, 10 l of blood was
drawn from the tail vein by nicking at different time intervals into hepa-
rinized glass capillary tubes (Fisherbrand Hematocrit). Viral DNA was
extracted from the blood samples using a DNeasy kit (Qiagen, Valencia,
CA) and further quantified by qPCR as described previously. Blood clear-
ance of viral genomes was plotted as a function of the viral genome copy
number versus time, and the data were fit into a biexponential model
using least-square regression analysis in GraphPad Prism software. The
distribution and elimination half-lives, as well as different rate constants
based on a two-compartment pharmacokinetic model, were calculated
using equations outlined in Table 1 as described previously (25). Pharma-
cokinetics parameters, standard errors, and goodness of fit from curve
fitting are listed in Tables 2 and 3.
Statistics. All data are expressed as measn 	 standard errors of the
mean (SEM) unless otherwise indicated. The two-tailed unpaired t test
was utilized for all statistical analysis, and P values of 
0.05 were consid-
ered significant unless otherwise indicated. Statistical evaluation of phar-
macokinetic parameters and goodness of fit was performed (data not
shown).
RESULTS
Intravenous sialidase alters tissue surface glycosylation pat-
terns in mice. Using lectin staining, we analyzed the endogenous
constitution of sialylated glycans in major mouse organs, as well as
the effect of administering intravenous sialidase on tissue surface
glycosylation patterns. First, BALB/c mice were intravenously in-
jected with PBS or recombinant sialidase from V. cholerae 3 h prior
to tissue harvesting/fixation. Sections of major organs were then
stained with fluorescein isothiocyanate (FITC)-labeled lectins,
specifically, ECL, which recognizes terminal galactose moieties on
Gal(1,4)N-GlcNAc, or MALI, which binds both 2,3-sialylated
and sulfated forms of Gal(1,4)N-GlcNAc. As shown in Fig. 1A,
FITC-ECL staining was barely discernible, while substantial
FITC-MALI staining was observed in murine heart, liver, brain,
and muscle. These observations suggest that the endogenous ex-
pression of asialoglycans containing terminal galactose is low
compared to that of 2,3-sialylated glycans in normal mouse tis-
sues. In contrast, intravenous injection of recombinant sialidase
markedly enhanced the FITC-ECL staining intensity in heart,
liver, and muscle tissue, while MALI staining showed a modest
decrease (Fig. 1B). Interestingly, murine brain displayed ECL
staining potentially localized to blood vessels alone, while MALI
staining remained more or less unaffected upon sialidase treat-
ment (Fig. 1B). These results correlate well with earlier in vitro
studies (28) and suggest that intravenous sialidase can effectively
desialylate glycoproteins and glycolipids, revealing the underlying
1,4-galactose moiety in major organs in vivo. We then exploited
these observations to further evaluate the impact of increasing
cognate glycan receptor density on AAV9 tropism in vivo.
High glycan binding avidity redirects systemic AAV9 to the
liver. We analyzed the effect of enzymatic desialylation on the
transduction profile of AAV9 vectors packaging a CBA promoter-
driven firefly luciferase transgene in vivo. Briefly, AAV9 vectors
were injected into the tail vein 3 h following intravenous admin-
istration of recombinant sialidase. To track the kinetics of lucifer-
ase transgene expression, live-animal bioluminescence images
were taken at different time intervals postinjection (Fig. 2A). As
seen in Fig. 2A, AAV9 displays a systemic transduction profile in
the PBS-treated mouse group (left), consistent with previous re-
ports (11, 26, 38). In the sialidase-treated group (Fig. 2A, right), a
predominantly liver-centric bioluminescent signal was observed,
accompanied by decreased signal in other systemic regions. Lucif-
erase transgene expression and viral genome copy numbers in
different tissue lysates were quantified at 2 weeks and 3 days
postinjection, respectively. As shown in Fig. 2B, the transduction
efficiency of AAV9 in the liver was 5-fold higher upon sialidase
treatment. Further, a substantial decrease in transduction effi-
ciency within the heart (10-fold) and skeletal muscle (14-fold)
was observed. Transgene expression levels in the murine brain are
relatively low in comparison with other organs and show no sig-
nificant change upon sialidase treatment. Consistent with these
observations, the biodistribution of viral genomes in the liver was
increased by 7-fold in the liver (Fig. 2C). Correspondingly, viral
genome copy numbers were decreased in the brain, heart, and
TABLE 2 Pharmacokinetic parameters and goodness of fit from curve fitting blood circulation data to a biexponential two-compartment model
Parametera
Value and standard error for treatment (virus):
PBS (AAV9) Sialidase (AAV9) PBS (AAV9-W503R)
Y0 6.86  10
10 	 9.81  109 9.89  1010 	 1.65  1010 8.62  1010 	 2.46  1010
A 3.75  1012 	 5.55  1010 8.79  1012 	 2.49  1010 3.94  1012 	 8.83  1011
B 3.11  1012 	 5.55  1010 1.10  1012 	 2.49  1010 4.68  1012 	 8.83  1011
 3.509 	 1.12 4.602 	 0.7836 1.752 	 3.566
 6.826  102 	 4.874  103 7.055  102 	 7.696  103 3.884 102 	 6.423  102
R2 0.9995 0.9999 0.7250
a A, B, , and  are biexponential parameters, and Y0 is the virus dose.
TABLE 3 Parameters describing the pharmacokinetics of AAV9 under
different glycan binding avidity conditions in vivo
Parameter
Value for:
AAV9 AAV9  sialidase AAV9-W503R
Glycan binding aviditya   
k21 (h
1) 1.63 0.57 0.97
ke (h
1) 0.15 0.57 0.07
k12 (h
1) 1.80 3.53 0.75
t1/2,dis (h) 0.38 0.20 0.92
t1/2,e (h) 4.72 1.22 9.87
a , decreased level; , endogenous level; , enhanced level.
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skeletal muscle (ranging from 2- to 5-fold) upon sialidase treat-
ment. These results suggest that surface glycan density in host
tissues strongly influences AAV tissue tropism. In particular, in-
creased availability of the galactose receptor in host tissue appears
to redirect AAV9 capsids from major systemic organs toward the
liver.
High glycan binding avidity results in AAV9 sequestration
within liver endothelial and Kupffer cells. To understand the
mechanism(s) underlying increased liver accumulation of AAV9, we
analyzed liver sequestration of viral capsids through immunohistol-
ogy. Briefly, mice were injected with AAV9 vectors 3 h after sialidase
or PBS treatment. At 15 min post-vector administration, livers and
hearts were harvested and processed as described in Materials and
Methods. Following PBS pretreatment, we observed sporadic immu-
nostaining for AAV9 capsids partially overlapping with endothelial
cells defined by FcRII/III/IV staining (anti-CD16/CD32) or other
cell types within the liver (Fig. 3A). In contrast, sialidase pretreatment
resulted in increased liver uptake of AAV9 capsids consistent with
increased galactose density (Fig. 3A). Further, increased immuno-
fluorescence associated with AAV9 capsids almost completely co-
localized with liver sinusoidal endothelial cells upon sialidase
treatment (Fig. 3A). We also observed substantially increased co-
localization of AAV9 capsids with Kupffer cells (anti-F4/80), in
addition to sinusoidal endothelial cells within the liver (Fig. 3B).
These results confirm the earlier observation that high glycan den-
sity in host tissues redirects AAV9 from systemic organs to the
FIG 1 Intravenous sialidase alters endogenous tissue glycosylation patterns in vivo. (A) Fluorescent lectin staining of heart, liver, brain, and skeletal muscle
tissues harvested from BALB/c mice. FITC-ECL was used to detect tissue glycans containing terminal 1,4-galactose and FITC-MALI to detect 2,3-sialylated
glycans. (B) Fluorescent lectin staining of heart, liver, brain, and skeletal muscle harvested from BALB/c mice administered intravenous sialidase to enzymatically
remove 2,3-sialic acid residues in vivo. Confocal micrographs were obtained using a Zeiss 710 confocal laser scanning microscope with a 40 objective at zoom
0.6. Scale bar  50 m.
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liver. The underlying mechanism can be attributed to markedly
increased sequestration of AAV9 capsids within the liver sinusoi-
dal endothelium and Kupffer cells.
Decreased glycan binding avidity detargets AAV9 from the
liver. We previously engineered a class of AAV9 mutants that have
selectively lost their ability to transduce the liver (26). As shown in
the previous study, one such mutant, AAV9-W503R, displayed
markedly lower transduction efficiency (1 log unit) in liver than
wild-type AAV9. In the current study, we evaluated the ability of
this mutant to bind surface-exposed galactose residues on Chinese
hamster ovary (CHO) Lec2 cells, which are permissive to AAV9
infection in vitro (6, 28). As seen in Fig. 4A, the AAV9-W503R
mutant is deficient in cell surface binding, with a binding potential
(Bmax/Kd=) that is 4.5-fold lower than that observed for wild-
type AAV9. Correspondingly, this mutant displays transduction
efficiency that is several orders of magnitude lower than that of
wild-type AAV9 in CHO Lec2 cells at different MOIs (Fig. 4B). We
then investigated the impact of such decreased glycan binding
avidity on liver sequestration of AAV9 and the W503R mutant
following intravenous administration. As seen in Fig. 4C, immu-
nohistological analysis revealed markedly less immunostaining
for AAV9-W503R than for AAV9 capsids. Moreover, while AAV9
capsids colocalized with FcRII/III/IV (anti-CD16/CD32 stain-
ing), which is specific for endothelial cells, as well as liver paren-
chyma, the AAV9-W503R mutant weakly colocalized with endo-
thelial cells alone (Fig. 4C). In addition, consistent with earlier
studies in our laboratory (26), we observed a lack of tdTomato
reporter gene expression in hepatocytes for AAV9-W503R, in
contrast to wild-type AAV9 (Fig. 4D). Taken together, these re-
sults suggest that decreased glycan binding is the underlying basis
for the liver-detargeted phenotype displayed by the AAV9-W503R
mutant.
The vascular endothelium constitutes a limiting barrier for
cardiac uptake of AAV9. We also evaluated the impact of altering
glycan binding avidity on the cardiac tropism of AAV9 in mice. As
seen in Fig. 5, immunostaining for AAV9 capsids (MAb ADK9;
red), as well as the endothelial marker FcRII/III/IV (anti-CD16/
CD32 staining), was markedly less than that observed in liver sec-
tions (Fig. 3). Moreover, unlike the liver, where viral particles are
dispersed among parenchymal and nonparenchymal cell types,
AAV9 capsids predominantly colocalize with the vascular endo-
thelium in the murine heart. This observation supports the notion
that transvascular transport is a likely prerequisite for viral entry
into cardiomyocytes, as proposed previously (16). Interestingly,
despite the dramatic increase in galactose receptor density, as
demonstrated by FITC-ECL staining, throughout cardiac tissue
following sialidase pretreatment, no changes in the pattern or ex-
tent of cardiac uptake of AAV9 capsids were observed compared
to a PBS-treated control. Instead, AAV9 capsids colocalized with
cardiac endothelium in a manner similar to that of PBS-treated
control animals. In addition, immunostaining for the low-bind-
ing-affinity mutant (AAV9-W503R) was significantly less at this
early time point, potentially due to decreased endothelial surface
interactions.
Altered glycan binding avidity affects the blood circulation
profile of AAV9. Several reports have demonstrated that AAV9
displays prolonged blood circulation in comparison with other
AAV strains in mice (16, 38). We hypothesized that the phenom-
enon could arise from low endogenous levels of terminal galactose
residues in murine tissue. To test this hypothesis, we first treated
FIG 2 High glycan binding avidity redirects systemic AAV9 to the liver.
(A) Live-animal bioluminescence images of AAV9-mediated luciferase
transgene expression in BALB/c mice. The animals were injected with PBS
(control; left) or recombinant sialidase (right) 3 h prior to AAV9-CBA-
luciferase administration via the tail vein. The images were obtained using
a Xenogen IVIS Lumina system at 2 days, 4 days, and 7 days postadminis-
tration (n  3). The rainbow scale represents RLU. (B) Luciferase trans-
gene expression in brain, heart, liver, and skeletal muscle tissue lysates.
Mice were intravenously injected with PBS or sialidase 3 h prior to injec-
tion of AAV9. Tissues were harvested at 2 weeks postadministration. Lu-
ciferase transgene expression (RLU) was normalized to total cellular pro-
tein in tissue lysates (n  3). The data are represented as means 	 SEM. (C)
AAV9 vector genome biodistribution in brain, heart, liver, and skeletal
muscle tissues harvested from BALB/c mice pretreated with PBS or siali-
dase at 3 days postadministration (n  3). Viral genome copy numbers in
different tissues/animals were obtained using quantitative PCR and nor-
malized to the total copy number of the constitutive mouse lamin gene in
host genomic DNA. The primer sequences utilized for qPCR are provided
in Materials and Methods. The data are represented as means 	 SEM.
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FIG 3 High glycan avidity potentiates AAV9 sequestration by liver sinusoidal endothelium and Kupffer cells. (A) Liver sections were obtained 15 min after
injection of AAV9 in BALB/c mice pretreated with intravenous PBS (middle row) or sialidase (bottom row). Tissue sections were stained with fluorescent lectin
to detect 1,4-galactose, FITC-ECL (green); anti-AAV9 capsid antibody, ADK9 (red); and anti-CD16/CD32 endothelial cell marker antibody (magenta). The
color images were merged, along with nuclear DAPI staining (blue), to generate the overlay panel. Untreated mouse liver is shown as a control (top row). The
large arrows indicate liver sinusoidal endothelial cells, and the small arrows indicate nonendothelial cells. (B) Liver sections obtained from BALB/c mice
pretreated with intravenous PBS or sialidase and immunostained with FITC-ECL (green), ADK9 (red), anti-F4/80 Kupffer cell marker antibody (magenta), and
nuclear DAPI staining (blue). The large arrows indicate liver sinusoidal endothelial cells, and the small arrows indicate Kupffer cells. Fluorescent micrographs
were obtained using a Zeiss 710 confocal laser scanning microscope with a 63 objective. Scale bar  50 m.
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mice with intravenous sialidase prior to AAV9 administration in
order to increase galactose receptor density in murine tissues, as
described previously. Viral genome copies in blood were then col-
lected at different time intervals and quantitated by qPCR analysis,
and the data were fit to a biexponential, two-compartment model
(Table 1) to obtain different pharmacokinetic parameters (Tables
2 and 3). As seen in Fig. 6A, high glycan binding avidity results in
rapid clearance of AAV9 from the blood (solid triangles), while
the low-binding-avidity mutant AAV9-W503R (solid circles) ap-
pears to persist longer in blood circulation than AAV9 circulating
under normal conditions. Specifically, increasing tissue glycan
density by sialidase treatment results in an 4 times shorter elim-
ination half-life (t1/2,e). In contrast, the AAV9-W503R mutant,
which is deficient in galactose binding, is eliminated twice as
slowly (10 h) from the blood circulation as AAV9 alone (4.7
h). Further, while the half-life of viral dissemination from blood to
tissue (t1/2,dis) is reduced by 2-fold upon sialidase treatment, the
parameter is extended from 0.4 h to 1 h (2.5-fold increase) for
the W503R mutant. Consistent with these observations, we note
that the blood-to-organ distribution rate constant (k12) and or-
gan-to-blood distribution rate constant (k21) are comparable in
mice injected with AAV9 alone. In contrast, k12 for AAV9 was
7-fold higher than k21 in mice pretreated with sialidase, support-
ing rapid tissue dissemination of injected virus particles. Further,
for the AAV9-W503R mutant, both the aforementioned rate pa-
rameters were lower than for AAV9, consistent with prolonged
blood residence time. Taken together, these results confirm that
the capsid-glycan interactions profoundly affect the pharmacoki-
netics of AAV9.
DISCUSSION
The liver is a prominent systemic organ featuring hepatocytes, as
well as a large proportion of cells belonging to the reticuloendo-
thelial system. Due to the large volume of circulating blood that
filters through the liver, the sinusoidal endothelial and Kupffer
cells in the organ play a major scavenging role in the uptake of
various macromolecules and pathogens (27, 29). A particularly
well-studied example of this is adenoviral sequestration within the
liver (8, 9, 13, 34). Most, if not all, naturally occurring isolates of
AAV studied to date display moderate to high transduction effi-
FIG 4 Low glycan binding avidity detargets AAV9-W503R from the liver. (A) The AAV9-W503R mutant displays decreased binding affinity for terminal
galactose residues on the surfaces of CHO Lec2 cells lacking sialic acid (n  4). Curve fitting based on a single-binding-site model was utilized to obtain binding
potential values (Bmax/Kd=) for the mutant and parental AAV9. The data are represented as means 	 SEM. (B) Transduction efficiencies of AAV9 and
AAV9-W503R on CHO Pro5 (constitutive glycan composition) and Lec2 (sialic acid-deficient) cells at different multiplicities of infection (n  4). Luciferase
transgene expression in cell lysates was analyzed 24 h postinfection; **, P 
 0.01; ***, P 
 0.005. The data are represented as means 	 SEM. (C) AAV9 and
AAV9-W503R accumulation in the livers of BALB/c mice at 15 min after intravenous administration. Immunostaining was carried out using anti-AAV9 capsid
antibody, ADK9 (red); anti-CD16/CD32 endothelial cell marker (magenta); and nuclear DAPI staining (blue). Fluorescent images were collected as described
above. The large arrows indicate liver sinusoidal endothelial cells, and the small arrows indicate nonendothelial cells. Scale bar  20 m. (D) Transgene
expression (tdTomato reporter) mediated by AAV9 and AAV9-W503R in liver and heart in BALB/c mice (n  3). Tissues were harvested and imaged 2 weeks
postinfection with a 10 objective.
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ciency within the liver (38). However, whether liver sequestration
mechanisms similar to those observed for adenoviruses prevail in
the case of AAV is not known.
In the current study, we investigated the potential role of gly-
can receptor binding avidity in AAV liver sequestration and sys-
temic spread using AAV9-galactose interactions as a model. No-
tably, the transduction profile and in vivo biodistribution of AAV9
were altered from systemic to hepatotropic under high glycan
binding avidity conditions. These observations were corroborated
by immunostaining studies, which revealed that increasing glycan
receptor binding avidity potentiates AAV9 sequestration within
the liver sinusoidal endothelium and Kupffer cells. In a corollary,
the AAV9-W503R mutant displayed low galactose binding affinity
and decreased liver uptake in mice. Further, our results suggest
that high-affinity receptor sites for AAV9 in mice are constitu-
tively low. This observation is not surprising, since it is well known
that glycans containing 1,4-linked galactose are extended by sia-
lylation or sulfation, although formation of poly-N-acetyllac-
tosamine (Gal1,4GlcNAc1) units has also been demonstrated
previously (32). The resulting modest glycan binding avidity
could explain the underlying basis for widespread, systemic tro-
pism and prolonged blood circulation displayed by AAV9 in com-
parison to other AAV serotypes in vivo. Strikingly, high glycan
binding avidity appears to adversely affect AAV9 uptake and
transduction in peripheral tissues, such as cardiac and skeletal
muscle. This effect can likely be attributed to the rapid blood clear-
ance of AAV9 under such conditions and highlights the limiting
role of vascular endothelium in viral dissemination. Our conclu-
sions are further supported by earlier studies by Kotchey and oth-
ers (16), which demonstrate that transendothelial transport of
FIG 5 Vascular endothelial cells limit cardiac uptake of AAV9 capsids. Confocal micrographs of cardiac tissue sections harvested from BALB/c mice
pretreated with PBS (second row from top) or sialidase (third row) obtained at 15 min after intravenous AAV9 injection. Immunostaining was carried out
using FITC-ECL (green), ADK9 (red), anti-CD16/CD32 (magenta), and nuclear DAPI (blue) staining. Colocalization of mutant AAV9-W503R with
vascular endothelium in the heart (bottom row) and cardiac tissue sections (top row) from untreated BALB/c mice is also shown. The arrows indicate
cardiac endothelium. Scale bar  50 m.
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AAV9 is a capacity-limited process that constitutes a significant
barrier to viral uptake by cardiomyocytes, but not hepatocytes.
Why is the AAV9-W503R mutant selectively detargeted from
the liver while transduction in peripheral tissues, such as the heart
and skeletal muscles, remains unaffected (26)? In the current
study, we determined that this mutant (as well as other liver-de-
targeted AAV9 mutants [S. Shen and A. Asokan, unpublished
data]) displays low galactose binding avidity in vitro and reduced
endothelial binding in vivo. These results are consistent with
W503R being recently identified as one of the key residues in-
volved in galactose recognition by AAV9 capsids (5). A potential
explanation for this phenomenon is that low glycan binding avid-
ity results in the doubling of the distribution half-life (t1/2,dis, 1
h), as well as the elimination half-life (t1/2,e, 9 h) of the mutant
compared to wild-type AAV9 (Table 3). Thus, it is likely that the
AAV9-W503R mutant significantly benefits from repeated circu-
lation through cardiac tissue, where traversing the vascular endo-
thelium appears to be a capacity-limited process. Such transendo-
thelial transport of viral particles might be redundant for
transduction in the liver, which contains open fenestrae that allow
free exchange of material between blood and the space of Disse
(29). These results are further corroborated by earlier studies with
AAV serotype 2, where abrogation of capsid binding to heparan
sulfate yielded liver-detargeted AAV2 mutants (14). One such
mutant, AAV2i8, which persists longer in blood than other AAV
strains, displays robust cardiac and skeletal muscle tropism with
the ability to traverse the vascular endothelium (3). Based on a
collective interpretation of results, we propose mathematical
models that will help predict the impact of capsid-glycan interac-
tions on AAV blood clearance, as well as transport between the
central (blood) compartment and the major peripheral (liver)
compartment (Fig. 6B and C). High glycan receptor binding avid-
ity likely increases the rate of viral dissemination from the blood to
the liver (k12), as well as rapid viral elimination from blood (ke) by
excretory mechanisms (Fig. 6B). In contrast, when glycan binding
avidity is low, both dissemination and elimination rate constants
are decreased, resulting in significantly longer blood circulation
times (Fig. 6C). It should be noted that while the glycan binding
avidity appears to influence the systemic fate, the secondary recep-
tor(s) for AAV9 likely contributes significantly to transduction in
vivo. Therefore, although virus-glycan interactions alone are un-
likely to provide a complete understanding of the biology of AAV,
it is tempting to speculate that the latter models could potentially
help predict liver sequestration of AAV in different species on the
basis of their respective glycosylation patterns.
In summary, our studies offer new insight into the role of gly-
cans in determining AAV tropism in vivo. In addition to resolving
the mechanistic basis of liver-detargeted AAV vectors, we provide
a potential general strategy for engineering any AAV strain by
modulating capsid-glycan interactions. Further, the results de-
scribed here underscore the importance of understanding species-
specific variation in glycosylation patterns. For instance, striking
differences in sialylation patterns between different tissues in
mice, rats, chimpanzees, and humans have been reported (2).
Such information could guide rational selection of preclinical an-
imal models for evaluating AAV vectors and might help better
predict clinical gene therapy outcomes.
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